Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.

abstract：BACKGROUND AND OBJECTIVE:TZP-101 is a selective, small molecule ghrelin receptor agonist in clinical development for the treatment of gastric motility disorders. The objectives of this study was to assess pharmacokinetic parameters of TZP-101 after multiple- and single-dose administration to healthy subjects and patien...

journal_title：Clinical drug investigation

authors： Wargin W,Thomas H,Clohs L,St-Louis C,Ejskjaer N,Gutierrez M,Shaughnessy L,Kosutic G

更新日期：2009-01-01 00:00:00

abstract：PURPOSE:Deferiprone (DFP), deferasirox (DFX) and deferoxamine (DFO) are used in thalassaemia major (TM) patients to treat chronic iron overload. We evaluated the cost-effectiveness of DFP, compared with DFX and DFO monotherapy, from an Italian healthcare system perspective. METHODS:A Markov model was used over a time ...

journal_title：Clinical drug investigation

authors： Pepe A,Rossi G,Bentley A,Putti MC,Frizziero L,D'Ascola DG,Cuccia L,Spasiano A,Filosa A,Caruso V,Hanif A,Meloni A

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Concomitant chemotherapy with radiotherapy is considered to be the standard of care for patients with head and neck cancer and good performance status. However, published reports on the cost effectiveness of this therapeutic approach are extremely rare. OBJECTIVE:The aim of this study was to estimate the co...

journal_title：Clinical drug investigation

authors： Chan AL,Leung HW,Huang SF

更新日期：2011-10-01 00:00:00

abstract：BACKGROUND:To evaluate the efficacy and safety of bronchoalveolar lavage (BAL) with diluted porcine surfactant in mechanically ventilated term infants with severe acute respiratory distress syndrome (ARDS) due to meconium aspiration syndrome (MAS). METHODS:Eight consecutive mechanically ventilated term infants with se...

journal_title：Clinical drug investigation

authors： Lista G,Bianchi S,Castoldi F,Fontana P,Cavigioli F

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:For patients with hypertension, effective 24-hour blood pressure (BP) control is vital to ensure protection against the early morning surge in BP and the associated increased risk of cardiovascular events. The aim of this analysis was to assess the 24-hour antihypertensive efficacy of olmesartan medoxomil (2...

journal_title：Clinical drug investigation

authors： Brunner HR,Arakawa K

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Tegoprazan is one of the potassium-competitive acid blockers (P-CABs). It exhibits its anti-secretory effects by competitively and reversibly blocking the availability of K+ of the H+, K+-ATPase. This study was designed to investigate the safety and pharmacokinetics of tegoprazan in healthy Ch...

journal_title：Clinical drug investigation

authors： He J,Cao G,Yu J,Wang J,Cheng N,Wu J,Zhang J,Wu X,Zhang B,Lu J,Chen S

更新日期：2021-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Ultra-long-acting insulin degludec (DEG) has a longer duration of action and less daily variability relative to other basal insulin (BI), and thus may benefit patients with type 1 diabetes mellitus (T1DM). We examined the impact of switching BI to DEG on glycemic control and insulin dose in T1...

journal_title：Clinical drug investigation

authors： Hamamoto Y,Honjo S,Fujimoto K,Tokumoto S,Ikeda H,Wada Y,Koshiyama H

更新日期：2017-09-01 00:00:00

abstract：BACKGROUND:Multimodal pain therapy including cyclo-oxygenase-2 inhibitors can result in optimal pain management with decreased opioid use and fewer opioid-related adverse events. Patient reported outcomes (PROs) help identify benefits in reduced opioid use and increased pain control. METHODS:In this randomized, double...

journal_title：Clinical drug investigation

authors： Langford RM,Joshi GP,Gan TJ,Mattera MS,Chen WH,Revicki DA,Chen C,Zlateva G

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:To evaluate the efficacy and safety of the natural platelet-activating factor receptor antagonist, BN 52021 (ginkgolide B) in the treatment of patients with severe sepsis related to Gram-negative and mixed bacterial infection. DESIGN AND SETTING:Prospective, randomised, double-blind, placebo-controlled, mult...

journal_title：Clinical drug investigation

authors： Albrecht DM,van Ackern K,Bender HJ,Hof H,Kox W,Victor N,Funk P,Kieser M,Köhler S,Krausch D,Marzi I,Menges T,Schmidt H

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Fentanyl buccal soluble film (FBSF) is a small, bilayered, water-soluble polymer film (BioErodible MucoAdhesive; BEMA™) that adheres to the buccal mucosa and rapidly delivers fentanyl into the systemic circulation. It is approved for the treatment of cancer breakthrough pain in adult opioid-to...

journal_title：Clinical drug investigation

authors： Finn AL,Vasisht N,Stark JG,Gever LN,Tagarro I

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Clinicians must choose between an increasing number of medications for the treatment of pulmonary arterial hypertension (PAH) with different routes of administration, adverse effects, costs and efficacies. We constructed a decision analysis to help inform treatment choices in PAH. METHODS:We c...

journal_title：Clinical drug investigation

authors： Garin MC,Clark L,Chumney EC,Simpson KN,Highland KB

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:To compare the bioavailability of two 15mg ambroxol lozenges with a commercial 30mg ambroxol tablet. DESIGN:Open-label, two-way crossover study. METHOD:Each formulation was randomly administered to 20 healthy Thai volunteers (ten male and ten female) with a 1-week washout period between formulations. After ...

journal_title：Clinical drug investigation

authors： Rojpibulstit M,Kasiwong S,Juthong S,Phadoongsombat N,Faroongsarng D

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Hypertension remains a major global health problem, and evidence suggests that the majority of patients will require two or more antihypertensive agents in order to reach specified BP targets. Combining two drugs from different classes has the potential to target different aspects of hypertensi...

journal_title：Clinical drug investigation

authors： Barrios V,Brommer P,Haag U,Calderón A,Escobar C

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Warfarin-related nephropathy is an unexplained acute kidney injury, and may occur in patients with supratherapeutic INR, in the absence of overt bleeding. Similar findings have been observed in rats treated with dabigatran etexilate. We conducted a prospective study in dabigatran etexilate-tre...

journal_title：Clinical drug investigation

authors： Molteni M,Crippa M,Orenti A,Polo Friz H,Menghini A,Tramacere P,Marano G,Cimminiello C,Boracchi P

更新日期：2019-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Several cases of facial paralysis have been reported following influenza vaccination; however, recent surveillance studies have not shown an increased risk. In this study, we analyzed the vaccine adverse event reporting system (VAERS) data to determine whether the facial paralysis reporting rat...

journal_title：Clinical drug investigation

authors： Kamath A,Maity N,Nayak MA

更新日期：2020-09-01 00:00:00

abstract：:This article discusses current practice in the treatment of conjunctivitis and how the use of topical moxifloxacin can increase therapeutic effectiveness, reduce treatment failures and, consequently, be cost effective and reduce the societal burden of the disorder. Current practice and effectiveness data were derived ...

journal_title：Clinical drug investigation

authors： Benitez-Del-Castillo J,Verboven Y,Stroman D,Kodjikian L

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVE:Addressing the needs of migraineurs by actively seeking patient feedback on disease-related disability and treatment satisfaction may lead to improved management and treatment outcomes. Patient feedback can be collected in postmarketing surveillance (PMS) studies. The objective of this PMS study was to evalua...

journal_title：Clinical drug investigation

authors： Diener HC,Evers S

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Vedolizumab, a humanized monoclonal antibody against the α4β7 integrin, is indicated for treatment of moderately to severely active ulcerative colitis or Crohn's disease. In this placebo-controlled, double-blind, randomized, single ascending-dose study, the pharmacokinetics, pharmacodynamics, ...

journal_title：Clinical drug investigation

authors： Rosario M,Wyant T,Leach T,Sankoh S,Scholz C,Parikh A,Fox I,Feagan BG

更新日期：2016-11-01 00:00:00

abstract：BACKGROUND:Recent clinical studies have documented the analgesic, anti-inflammatory, antioxidative and anxiolytic effects of exogenous melatonin. The pharmacokinetic properties of melatonin have primarily been investigated in experimental studies. OBJECTIVE:The aim of this study was to estimate the pharmacokinetics of...

journal_title：Clinical drug investigation

authors： Harpsøe NG,Andersen LP,Mielke LV,Jønsson B,Jenstrup MT,Gögenur I,Rosenberg J

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:First-line treatment of chronic phase (CP) chronic myeloid leukemia (CML) is based on the first-generation tyrosine kinase inhibitor (TKI) imatinib or the second-generation TKIs dasatinib or nilotinib. Thanks to the efficacy of TKIs, CML has switched from a fatal to a 'chronic' pathology, and ...

journal_title：Clinical drug investigation

authors： Bettiol A,Marconi E,Lombardi N,Crescioli G,Gherlinzoni F,Walley T,Vannacci A,Chinellato A,Giusti P

更新日期：2018-09-01 00:00:00

abstract：:Early initiation of rational and effective combination therapy consisting of antihypertensive drugs with two different and complementary mechanisms of actions is increasingly becoming accepted in clinical practice and by guidelines as a first-line approach to control blood pressure (BP) and prevent cardiovascular outc...

journal_title：Clinical drug investigation

authors： da Silva PM

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Little is known about the effects of the calcium channel antagonist manidipine when it is added as a third drug in non-controlled hypertensive patients with diabetes mellitus receiving dual antihypertensive therapy. The aim of this study was to evaluate the response in terms of blood pressure (...

journal_title：Clinical drug investigation

authors： Martell-Claros N,de la Cruz JJ

更新日期：2011-01-01 00:00:00

abstract：:None of the available antiemetics is entirely effective, perhaps because most of them act through the blockade of one receptor. There is a possibility that a combination of antiemetics with different sites of activity would be more effective than one drug alone for prophylaxis against postoperative nausea and vomiting...

journal_title：Clinical drug investigation

authors： Fujii Y

更新日期：2002-09-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Cancer pain affects patients at all stages of the disease and there are clear guidelines for its management. Morphine is considered the first-choice strong opioid in the treatment of moderate-to-severe pain; however, numerous studies have shown that oxycodone controlled-release (CR) has a simi...

journal_title：Clinical drug investigation

authors： Silvestri B,Bandieri E,Del Prete S,Ianniello GP,Micheletto G,Dambrosio M,Sabbatini G,Endrizzi L,Marra A,Aitini E,Calorio A,Garetto F,Nastasi G,Piantedosi F,Sidoti V,Spanu P

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Bisphosphonates are commonly used to treat and prevent osteoporosis. These compounds have unusual pharmacokinetic characteristics because they bind strongly to bone, and a portion becomes buried under newly formed bone. Once incorporated into bone tissue, the subsequent release during bone remo...

journal_title：Clinical drug investigation

authors： Lasseter KC,Porras AG,Denker A,Santhanagopal A,Daifotis A

更新日期：2005-01-01 00:00:00

abstract：OBJECTIVE:To evaluate the cost effectiveness of subcutaneous interferon-beta-1a (IFNbeta-1a) 44mug three times weekly in relapsing-remitting multiple sclerosis (RRMS) using an econometric model. METHODS:Data on RRMS patients treated with IFNbeta-1a 22 or 44mug subcutaneously three times weekly or placebo for up to 4 y...

journal_title：Clinical drug investigation

authors： Lepen C,Coyle P,Vollmer T,Blumhardt L,Lilliu H,Beresniak A

更新日期：2003-01-01 00:00:00

abstract：:Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall,...

journal_title：Clinical drug investigation

authors： Boyd SD,Tracy L,Komatsu TE,Harrington PR,Viswanathan P,Murray J,Sherwat A

更新日期：2017-04-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Injectable collagenase Clostridium histolyticum is efficacious in correcting Dupuytren's contracture as assessed by changes in the angle of contracture and range of motion (ROM). However, clinically important changes in ROM have not been evaluated in depth. The objective of this secondary analy...

journal_title：Clinical drug investigation

authors： Witthaut J,Bushmakin AG,Gerber RA,Cappelleri JC,Le Graverand-Gastineau MP

更新日期：2011-11-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:The implementation of chronic obstructive pulmonary disease (COPD) guidelines in the real-world setting remains low. Pulmonologists should participate in the new paradigms of chronicity of COPD, by providing their knowledge, expertise, innovation and research. The objective of this study was to...

journal_title：Clinical drug investigation

authors： de Miguel-Díez J,Jiménez-García R,López de Andrés A,Zaragoza Arnáez F

更新日期：2019-07-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Matrix metalloproteinases (MMPs) are proteases with different biological and pathological activities, and many have been linked to several diseases. Targeting individual MMPs may offer a safer therapeutic potential for several diseases. We assessed the safety, tolerability, and pharmacokinetic...

journal_title：Clinical drug investigation

authors： Abd-Elaziz K,Voors-Pette C,Wang KL,Pan S,Lee Y,Mao J,Li Y,Chien B,Lau D,Diamant Z

更新日期：2021-01-01 00:00:00